Cardiovascular disease, heart failure and COVID-19.
作者信息
Faconti Luca, Chowienczyk Philip J, Shah Ajay M
机构信息
School of Cardiovascular Medicine and Sciences, King's College London, Department of Clinical Pharmacology, St Thomas' Hospital, UK.
School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Research Excellence, UK.
出版信息
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926903. doi: 10.1177/1470320320926903.
Abstract
摘要
相似文献
1
Cardiovascular disease, heart failure and COVID-19.心血管疾病、心力衰竭与2019冠状病毒病
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926903. doi: 10.1177/1470320320926903.
2
Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.致编辑的信：血管紧张素转换酶2：盟友还是特洛伊木马？对SARS-CoV-2相关心血管并发症的影响
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1080-H1083. doi: 10.1152/ajpheart.00215.2020. Epub 2020 Mar 30.
3
COVID-19 in patients with cardiovascular diseases.心血管疾病患者中的新型冠状病毒肺炎
Arch Cardiovasc Dis. 2020 Apr;113(4):225-226. doi: 10.1016/j.acvd.2020.03.009. Epub 2020 Mar 31.
4
COVID-19 and the cardiovascular system.新型冠状病毒肺炎与心血管系统。
Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.
5
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
6
COVID-19 and Cardiovascular Disease.新型冠状病毒肺炎与心血管疾病。
Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.
7
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.SARS-CoV-2 与心血管并发症：从分子机制到药物治疗管理。
Biochem Pharmacol. 2020 Aug;178:114114. doi: 10.1016/j.bcp.2020.114114. Epub 2020 Jun 21.
8
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?在新冠疫情期间，血管紧张素受体阻断药物是否可能有害？
J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450.
9
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.心力衰竭背景下COVID-19对肾素-血管紧张素系统的干扰
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
10
COVID-19 and the pulmonary vascular injury.新型冠状病毒肺炎与肺血管损伤
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320972276. doi: 10.1177/1470320320972276.
引用本文的文献
1
NOX2 and NOX5 are increased in cardiac microvascular endothelium of deceased COVID-19 patients.在已故 COVID-19 患者的心脏微血管内皮中，NOX2 和 NOX5 增加。
Int J Cardiol. 2023 Jan 1;370:454-462. doi: 10.1016/j.ijcard.2022.10.172. Epub 2022 Nov 2.
2
Outcomes of coronavirus disease-2019 among veterans with pre-existing diagnosis of heart failure.新冠病毒疾病 2019 患者中伴有预先存在的心力衰竭诊断的结局。
ESC Heart Fail. 2021 Jun;8(3):2338-2344. doi: 10.1002/ehf2.13291. Epub 2021 Mar 16.
3
COVID-19 in a Three-Year-Old Girl With Total Anomalous Pulmonary Venous Return: A Case Report.一名患有完全性肺静脉异位引流的三岁女童的新型冠状病毒肺炎：病例报告
Cureus. 2020 Nov 29;12(11):e11768. doi: 10.7759/cureus.11768.
4
The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic.新冠肺炎合并心血管疾病患者的病死率：全球卫生挑战与当前大流行中的范例
Curr Pharmacol Rep. 2020;6(6):315-324. doi: 10.1007/s40495-020-00239-0. Epub 2020 Sep 15.
本文引用的文献
1
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.中国 COVID-19 患者 1590 例的合并症及其影响：一项全国性分析。
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.00547-2020. Print 2020 May.
2
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?在新冠疫情期间，血管紧张素受体阻断药物是否可能有害？
J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
5
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
6
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
7
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
8
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.流感疫苗接种与高危患者心血管结局的关联：一项荟萃分析。
JAMA. 2013 Oct 23;310(16):1711-20. doi: 10.1001/jama.2013.279206.
9
Acute pneumonia and the cardiovascular system.急性肺炎与心血管系统。
Lancet. 2013 Feb 9;381(9865):496-505. doi: 10.1016/S0140-6736(12)61266-5. Epub 2013 Jan 16.
10
Angiotensin II and oxidative stress in the failing heart.血管紧张素 II 与心力衰竭中的氧化应激。
Antioxid Redox Signal. 2013 Oct 1;19(10):1095-109. doi: 10.1089/ars.2012.4588. Epub 2012 May 3.
Zotero 插件